New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 28, 2013
04:55 EDTATOS, ATOS, RHHBY, RHHBY, SQNM, SQNM, GHDX, GHDX, SAP, SAP, AET, AET, IBM, IBM, UNH, UNHPMWC, Inc to host a conference
Personalized Medicine World Conference is being held in Mountain View, California on January 28-29.
News For ATOS;RHHBY;SQNM;GHDX;SAP;AET;IBM;UNH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
July 16, 2015
09:08 EDTUNHOn The Fly: Pre-market Movers
Subscribe for More Information
09:06 EDTUNHUnitedHealth expects EPS to accelerate in 2016
Subscribe for More Information
08:30 EDTUNHUnitedHealth reports Q2 Optum revenue $13.6B
Subscribe for More Information
07:18 EDTIBMIBM July weekly volatility elevated into Q2 and outlook
Subscribe for More Information
06:06 EDTUNHUnitedHealth reports Q2 Employer & Individual revenue up 10% to $11.8B
Subscribe for More Information
06:04 EDTUNHUnitedHealth reports Q2 medical care ratio 81.4%
Medical cost trends remained controlled and consistent with management expectations. Reserves developed favorably by a total of $90M in the quarter. Reports Q2 operating cost ratio of 16.1%.
06:03 EDTUNHUnitedHealth raises FY15 EPS to $6.25-$6.35 from $6.15-$6.30, consensus $6.26
Subscribe for More Information
06:01 EDTUNHUnitedHealth reports Q2 EPS $1.64, consensus $1.59
Subscribe for More Information
July 15, 2015
15:42 EDTUNHUnitedHealth July 125 straddle priced for 2.8% movement into Q2
14:53 EDTUNHNotable companies reporting before tomorrow's open
Subscribe for More Information
14:38 EDTSAPSAP upgraded to Buy from Hold at Deutsche Bank
12:35 EDTUNHUnitedHealth July volatility elevated into Q2 and outlook
Subscribe for More Information
08:53 EDTAETAetna decline creates favorable entry point, says Argus
Subscribe for More Information
08:12 EDTIBMIBM and RTI International partner for data-driven development
Subscribe for More Information
July 14, 2015
17:11 EDTSAPMicrosoft M&A chief says Salesforce sale 'depends on' Benioff, Fortune reports
Subscribe for More Information
17:02 EDTUNHCatamaran approves acquisition by UnitedHealth
Subscribe for More Information
08:14 EDTGHDXGenomic Health reports new study on Oncotype DX
Subscribe for More Information
08:10 EDTIBMIBM and Mubdala sign agreement to bring Watson to MENA
Subscribe for More Information
07:27 EDTAETAetna in best position among health insurers for earnings beat, says Wells Fargo
Wells Fargo believes that Aetna is in the best position among health insurers to report better than expected earnings. The firm says that the company's cost trend remains manageable and below guidance. It keeps an Outperform rating on the shares.
06:04 EDTRHHBYRoche says atezolizumab met primary endpoint in IMvigor 210 trial
Roche announced that in the IMvigor 210 study, the investigational cancer immunotherapy atezolizumab shrank tumors -- objective response rate, ORR, the primary end point of this Phase II study -- in people with locally advanced or metastatic urothelial bladder cancer who had progressed on initial treatment. High amounts of PD-L1 expression by a person’s cancer correlated with increased response to the medicine. Adverse events were consistent with what has been previously observed for atezolizumab. Sandra Horning, M.D., chief medical officer and head of Global Product Development, said, “We plan to present results at an upcoming medical meeting and will discuss next steps with health authorities to bring a new treatment option to patients as soon as possible.” Last year, the U.S. FDA granted Breakthrough Therapy Designation for atezolizumab in people whose metastatic bladder cancer expressed PD-L1. This designation is designed to expedite the development and review of medicines intended to treat serious diseases. In addition to the IMvigor 210 study, Roche has an ongoing randomised Phase III study, IMvigor 211, comparing atezolizumab with standard-of-care chemotherapy in people who have relapsed UBC, and a planned Phase III study, IMvigor 010, that will evaluate atezolizumab compared with observation in people with early-stage muscle-invasive bladder cancer who are selected for PD-L1 expression and are at risk for recurrence.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use